Author [ Title(Desc)] Type Year
Filters: First Letter Of Title is G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, et al. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord. 2015.
Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, et al. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019;15:214-222.
Coyne AN, Zaepfel BL, Hayes L, Fitchman B, Salzberg Y, Luo E-C, Bowen K, Trost H, Aigner S, Rigo F, et al. GC Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD. Neuron. 2020.
Rothstein JD, Baskerville V, Rapuri S, Mehlhop E, Jafar-Nejad P, Rigo F, Bennett F, Mizielinska S, Isaacs A, Coyne AN. GC targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons. Acta Neuropathol. 2023;147(1):1.
Li J, Tuo D, Cheng T, Deng Z, Gan J. GCF2 mediates nicotine-induced cancer stemness and progression in hepatocellular carcinoma. Ecotoxicol Environ Saf. 2024;271:115952.
Murgia A, Mancuso L, Manis C, Caboni P, Cao G. GC-MS metabolomics analysis of mesenchymal stem cells treated with copper oxide nanoparticles. Toxicol Mech Methods. 2016:1-9.
Wang H, Wang X, Archer TK, Zwaka TP, Cooney AJ. GCNF-dependent activation of cyclin D1 expression via repression of Mir302a during ES cell differentiation. Stem Cells. 2014.
Li Y, Guo R, Wang L, Li S, Zhu Z, Tu P. G-CSF administration results in thrombocytopenia by inhibiting differentiation of hematopoietic progenitors into megakaryocytes. Biochem Pharmacol. 2019:113624.
Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol. 2015;195(4):1341-9.
Zhao S-Q, Li J-M. [G-CSF and Its Receptor in Hematonosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(3):871-877.
D'Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Sousa PSantos E, Bruneau J, Fouquet G, Zavala F, et al. G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease. Sci Transl Med. 2015;7(281):281ra42.
Li Y, Qiu X, Lei Y, Zhou R. G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis. Ann Med. 2024;56(1):2329140.
Antar A, Otrock ZK, Kharfan-Dabaja MA, Ghaddara HA, Kreidieh N, Mahfouz R, Bazarbachi A. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis. Bone Marrow Transplant. 2015.
Aymonnier K, Bosetta E, Leborgne NGF, Ullmer A, Le Gall M, De Chiara A, Salnot V, Mani S, Scapini P, Wicks I, et al. G-CSF reshapes the cytosolic PCNA scaffold and modulates glycolysis in neutrophils. J Leukoc Biol. 2023.
Straka C, Salwender H, Schnabel B, Sandherr M, Wandt H, Hübel K, Scheid C, Metzner B, Hentrich M, Franke D, et al. G-CSF response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. Leuk Lymphoma. 2014.
Alghamri MS, McClellan BL, Avvari RP, Thalla R, Carney S, Hartlage MS, Haase S, Ventosa M, Taher A, Kamran N, et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv. 2021;7(40):eabh3243.
Aerts-Kaya F, Kiliç E, Köse S, Aydin G, Cagnan I, Kuşkonmaz B, Uckan-Cetinkaya D. G-CSF treatment of healthy pediatric donors affects their hematopoietic microenvironment through changes in bone marrow plasma cytokines and stromal cells. Cytokine. 2020;139:155407.
Wen Q, Kong Y, Zhao H-Y, Zhang Y-Y, Han T-T, Wang Y, Xu L-P, Zhang X-H, Huang X-J. G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019.
Li Q, Luo J, Zhang Z, Liu L, Luo L, Yang G, Liu R, Shi L, Huang R, Wu M, et al. G-CSF-mobilized blood and bone marrow grafts as the source of stem cells for HLA-identical sibling transplantation in patients with thalassemia major. Biol Blood Marrow Transplant. 2019.
Wang L, Wu C, Xu J, Gong Z, Cao X, Huang J, Dong H, Zhu W, Huang F, Zhou C, et al. GC‑MSC‑derived circ_0024107 promotes gastric cancer cell lymphatic metastasis via fatty acid oxidation metabolic reprogramming mediated by the miR‑5572/6855‑5p/CPT1A axis. Oncol Rep. 2023;50(1).
Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022.
Gargett T, Ebert LM, Truong NTH, Kollis PM, Sedivakova K, Yu W, Yeo ECF, Wittwer NL, Gliddon BL, Tea MN, et al. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. J Immunother Cancer. 2022;10(9).
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. GD3 ganglioside is a promising therapeutic target for glioma patients. Neurooncol Adv. 2024;6(1):vdae038.
Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology. 2014.
Ben Driss L, Lian J, Walker RG, Howard JA, Thompson TB, Rubin LL, Wagers AJ, Lee RT. GDF11 and aging biology - controversies resolved and pending. J Cardiovasc Aging. 2023;3(4).